Pharmaceutical

UK MHRA approves ViiV Healthcare’s cabotegravir formulations for HIV-1

The UK MHRA approved two formulations of ViiV Healthcare’s cabotegravir, offering a new prevention option for HIV-1 infection.

May 7, 2024 - 00:00
UK MHRA approves ViiV Healthcare’s cabotegravir formulations for HIV-1
The UK MHRA approved two formulations of ViiV Healthcare’s cabotegravir, offering a new prevention option for HIV-1 infection.
Read the original article

Tags:

Previous Article

Lantern Pharma and Oregon partner to develop cancer treatment

Next Article

Sentynl acquires Eiger’s Zokinvy for progeria treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: It’s past time to address the problem of indoor air quality. A new technology can help

Opinion: It’s past time to address the problem of indoo...

Jun 28, 2023

Genentech signs nanoparticle deal worth up to $644m with GenEdit

Genentech signs nanoparticle deal worth up to $644m wit...

Jan 23, 2024

STAT+: Biogen to acquire Reata Pharmaceuticals in $7 billion deal

STAT+: Biogen to acquire Reata Pharmaceuticals in $7 bi...

Jul 28, 2023